| 摘要 |
<p>The present invention is directed to a method of diagnosing Alzheimer's disease involving analysis of a test sample in such a way that β-amyloid1-42 or Aβ3pE is completely or nearly completely (ie., thoroughly) dissociated from binding proteins prior t the analysis of the levels of βamyloid1-42 or Aβ3pE.</p> |
